Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal Cuff Brachytherapy + Chemotherapy in High-Risk Endometrial Cancer
NCT03189446Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2017
- Primary completion
- Dec 2019
- Countries
- 1
- Sponsor
- University of Oklahoma
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Conditions
- endometrial cancer (EC)
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and Paclitaxel Micelles for Injection in endometrial cancer (EC), sponsored by University of Oklahoma. Primary endpoint: Number of Patients Completing the Protocol at 4 months. Started Oct 2017; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Vaginal Cuff Brachytherapy + Chemotherapy
Vaginal cuff brachytherapy followed by Carboplatin and Dose Dense Paclitaxel.
03
Endpoints
Primary
Number of Patients Completing the Protocol
Secondary
Frequency of Adverse Events Related to Acute Toxicity During Treatment
Sites of Failure
Recurrence-free Survival
Contributing Cause of Death
Overall Survival
Beyond the preview
Go deeper on NCT03189446.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189446.